ArticleAmerican journal of translational research2025
LncRNA SNHG5 promotes the invasion and proliferation of oropharyngeal squamous cell carcinoma by regulating the miR-21/PTEN signaling pathway.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo delineate the functional role of long non-coding RNA (LncRNA) SNHG5 in oropharyngeal squamous cell carcinoma (OPSCC).
methodsThe expression of LncRNA SNHG5 in paired tumor/adjacent tissues and cell lines (HN6 vs. HIOEC) were detected, and the relationship between LncRNA SNHG5 expression in cancer tissues and the clinicopathological characteristics and prognosis of patients was analyzed. The functional characterization including proliferation, expression of LncRNA SNHG5, miR-21, PTEN, VEGF, MMP-9, cell invasion, as well as cell apoptosis were detected in siRNA-mediated SNHG5 knockdown in HN6 cells.
resultsTumor tissues exhibited higher SNHG5 expression versus adjacent mucosa (P<0.001). Elevated SNHG5 positively correlated with advanced TNM staging, lymph node metastasis, and poor differentiation (P<0.05). Patients with high SNHG5 showed significantly reduced 5-year overall survival (P=0.035). SNHG5 silencing decreased proliferation and invasion capacity, while increasing apoptosis. Mechanistically, SNHG5 knockdown downregulated oncogenic miR-2, VEGF, and MMP-9, while restoring tumor-suppressive PTEN expression.
conclusionOur findings suggest SNHG5 is a master oncogenic regulator in OPSCC that mechanistically promotes tumor progression via miR-21/PTEN pathway activation. The strong association between SNHG5 overexpression and adverse clinicopathological features, coupled with its prognostic independence, positions this lncRNA as a promising therapeutic target and molecular stratification biomarker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.